These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 19139476)

  • 41. Warfarin pharmacogenetics: a controlled dose-response study in healthy subjects.
    Kadian-Dodov DL; van der Zee SA; Scott SA; Peter I; Martis S; Doheny DO; Rothlauf EB; Lubitz SA; Desnick RJ; Halperin JL
    Vasc Med; 2013 Oct; 18(5):290-7. PubMed ID: 24029542
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Potential clinical and economic outcomes of CYP2C9 and VKORC1 genotype-guided dosing in patients starting warfarin therapy.
    You JH; Tsui KK; Wong RS; Cheng G
    Clin Pharmacol Ther; 2009 Nov; 86(5):540-7. PubMed ID: 19571807
    [TBL] [Abstract][Full Text] [Related]  

  • 43. VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients.
    Obayashi K; Nakamura K; Kawana J; Ogata H; Hanada K; Kurabayashi M; Hasegawa A; Yamamoto K; Horiuchi R
    Clin Pharmacol Ther; 2006 Aug; 80(2):169-78. PubMed ID: 16890578
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evaluation of genetic factors for warfarin dose prediction.
    Caldwell MD; Berg RL; Zhang KQ; Glurich I; Schmelzer JR; Yale SH; Vidaillet HJ; Burmester JK
    Clin Med Res; 2007 Mar; 5(1):8-16. PubMed ID: 17456829
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin.
    Gage BF; Eby C; Milligan PE; Banet GA; Duncan JR; McLeod HL
    Thromb Haemost; 2004 Jan; 91(1):87-94. PubMed ID: 14691573
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Impact of age, CYP2C9 genotype and concomitant medication on the rate of rise for prothrombin time during the first 30 days of warfarin therapy.
    Wilke RA; Berg RL; Vidaillet HJ; Caldwell MD; Burmester JK; Hillman MA
    Clin Med Res; 2005 Nov; 3(4):207-13. PubMed ID: 16303885
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of polymorphisms in the cytochrome P450 CYP2C9 gene on warfarin anticoagulation.
    Adcock DM; Koftan C; Crisan D; Kiechle FL
    Arch Pathol Lab Med; 2004 Dec; 128(12):1360-3. PubMed ID: 15578879
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Warfarin initiation and the potential role of genomic-guided dosing.
    Lee CR
    Clin Med Res; 2005 Nov; 3(4):205-6. PubMed ID: 16303884
    [No Abstract]   [Full Text] [Related]  

  • 49. Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues.
    Gage BF; Lesko LJ
    J Thromb Thrombolysis; 2008 Feb; 25(1):45-51. PubMed ID: 17906972
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Role of pharmacogenomics in the management of traditional and novel oral anticoagulants.
    Cavallari LH; Shin J; Perera MA
    Pharmacotherapy; 2011 Dec; 31(12):1192-207. PubMed ID: 22122181
    [TBL] [Abstract][Full Text] [Related]  

  • 51. CYP2C9 Mutation Affecting the Individual Variability of Warfarin Dose Requirement.
    Kim YB; Ko MJ; Lee DG; Do JG; Hwang JH
    Ann Rehabil Med; 2012 Dec; 36(6):857-60. PubMed ID: 23342320
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical applicability of sequence variations in genes related to drug metabolism.
    Stojiljkovic M; Patrinos GP; Pavlovic S
    Curr Drug Metab; 2011 Jun; 12(5):445-54. PubMed ID: 21453274
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing.
    Meckley LM; Gudgeon JM; Anderson JL; Williams MS; Veenstra DL
    Pharmacoeconomics; 2010; 28(1):61-74. PubMed ID: 20014877
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Warfarin pharmacogenetic trials: is there a future for pharmacogenetic-guided dosing?
    Scott SA; Lubitz SA
    Pharmacogenomics; 2014 Apr; 15(6):719-22. PubMed ID: 24897277
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Warfarin Pharmacogenomics in Diverse Populations.
    Kaye JB; Schultz LE; Steiner HE; Kittles RA; Cavallari LH; Karnes JH
    Pharmacotherapy; 2017 Sep; 37(9):1150-1163. PubMed ID: 28672100
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Role of pharmacodiagnostic of CYP2C9 variants in the optimization of warfarin therapy in Malaysia: a 6-month follow-up study.
    Ngow H; Teh LK; Langmia IM; Lee WL; Harun R; Ismail R; Salleh MZ
    Xenobiotica; 2008 Jun; 38(6):641-51. PubMed ID: 18570163
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Rapid genotyping of single nucleotide polymorphisms influencing warfarin drug response by surface-enhanced laser desorption and ionization time-of-flight (SELDI-TOF) mass spectrometry.
    Yang S; Xu L; Wu HM
    J Mol Diagn; 2010 Mar; 12(2):162-8. PubMed ID: 20075209
    [TBL] [Abstract][Full Text] [Related]  

  • 58. CYP2C9 promoter variable number tandem repeat polymorphism regulates mRNA expression in human livers.
    Wang D; Sun X; Gong Y; Gawronski BE; Langaee TY; Shahin MH; Khalifa SI; Johnson JA
    Drug Metab Dispos; 2012 May; 40(5):884-91. PubMed ID: 22289258
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Interaction potential between cranberry juice and warfarin.
    Pham DQ; Pham AQ
    Am J Health Syst Pharm; 2007 Mar; 64(5):490-4. PubMed ID: 17322161
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Genetic testing before anticoagulation? A systematic review of pharmacogenetic dosing of warfarin.
    Kangelaris KN; Bent S; Nussbaum RL; Garcia DA; Tice JA
    J Gen Intern Med; 2009 May; 24(5):656-64. PubMed ID: 19306050
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.